[Uremic syndrome: Pathogenesis, pathophysiology, and therapy].
Hara
Shigeko
S
Health Medical Center, Toranomon Hospital.
D000686:Amyloidosis / Q000209:etiology; D000804:Angiotensin II / Q000037:antagonists & inhibitors; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D002114:Calcinosis / Q000209:etiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002606:Charcoal / Q000008:administration & dosage; D003956:Dialysis / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy; D014118:Toxins, Biological; D014511:Uremia / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D014652:Vascular Diseases / Q000209:etiology
D047228:Angiotensin II Type 1 Receptor Blockers; D002121:Calcium Channel Blockers; D014118:Toxins, Biological; C026865:uremia middle molecule toxins; D000804:Angiotensin II; D002606:Charcoal